Liproxstatin-1 is able to suppress ferroptosis in cells, in Gpx4(-/-) mice, and in a pre-clinical model of ischaemia/reperfusion-induced hepatic damage.

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

利普司他丁-1;Liproxstatin1

white to light brown Powder

DMSO : 63 mg/mL (184.8 mM)
Ethanol : 16 mg/mL (46.9 mM)

ferroptosis

Liproxstatin-1 is able to inhibit ferroptosis in the low nanomolar range and inhibit the growth of Gpx4−/−cells with IC50 of 22 nM. Liproxstatin-1 (50 nM) completely prevents lipid peroxidation in Gpx4−/−cells. Liproxstatin-1 (200 nM) protects against FINs, such as BSO (10 µM), erastin (1 µM) and RSL3 (0.5 µM), in a dose dependent manner, whereas it fails to rescue cell death induced by staurosporine (0.2 µM) and H2O2 (200 µM).

Liproxstatin-1 remarkably extends survival compared with the vehicle-treated group, delays ferroptosis in tubular cells, and mitigates tissue injury in ischaemia/reperfusion-induced liver injury.